2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports In Oncology 2021, 14: 430-438. PMID: 33790764, PMCID: PMC7983595, DOI: 10.1159/000514345.Peer-Reviewed Original ResearchMetastatic extramammary Paget's diseaseExtramammary Paget's diseaseStandard therapyPaget's diseaseTreatment responsePrimary cutaneous extramammary Paget diseaseCutaneous extramammary Paget's diseaseHigh PD-L1 expressionHigh tumor mutation burdenCycles of ipilimumabDurable partial responseImmune checkpoint inhibitionImmune checkpoint inhibitorsPD-L1 expressionCheckpoint inhibitor immunotherapyRare clinical entityTumor mutation burdenMetastatic tumor tissueCombination ipilimumabCheckpoint inhibitorsMetastatic diseaseCytotoxic chemotherapyPartial responseCheckpoint inhibitionClinical entity
2018
Standardizing goals of care (GoC) documentation for new patients with metastatic disease.
Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.Peer-Reviewed Original ResearchGOC discussionsGOC documentationPatient-centered cancer carePalliative care teamEligible patientsSmart phrasesMetastatic diseaseNursing assessmentPatient assessmentCancer careQuality improvement toolsCare teamMetastatic cancerThird visitNew patientsProvider timeCare documentationPatientsBusy practiceProvider capacityBaseline dataElectronic documentationProvidersImprovement toolsFacilitative strategies